First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation
R. Kim, Shruti Sharma, Tim Meyer, Debashis Sarker, Teresa Macarulla, Mi‐Kyung Sung, Su Pin Choo, Hengxin Shi, Oleg Schmidt‐Kittler, Corinne Clifford, Beni B. Wolf, Josep M. Llovet (2016). First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation. European Journal of Cancer, 69, pp. S41-S41, DOI: 10.1016/s0959-8049(16)32704-6.
